Hyderabad, March 17
Aurobindo Pharma Ltd (APL) announced that Bristol-Myers Squibb Company (BMS) has given licence to market two important anti-retrovirals (ARVs) - Stavudine and Didanosine - in 49 countries, including South Africa.
In a press release here on Friday, the company said one of the objectives of the licence was to increase access of the products for the benefit of people in the treatment of HIV/AIDS.
Aurobindo has the largest number of approved products by the United States Food and Drug Administration (USFDA) for the ARV segment. The company said it continued to play an anchor role in the management of AIDS by supplying APIs (active pharmaceutical ingredients) and formulations for most of the ARVs.
The USFDA had already approved under the PEPFAR programme the ARV drug Stavudine capsules 30 mg and 40 mg and Stavudine oral solution 1 mg/ml. Further, the US drug authority had also approved the relevant API and formulation facilities of Aurobindo Pharma.
Thanking BMS for granting licence to market two ARVs, Aurobindo Pharma said it was hopeful of such gestures by various MNCs in the world to enhance the access of quality ARV generics for the benefit of people.Related Stories:
Aurobindo HIV drug gets USFDA nod
Aurobindo gets 6 ARVs WHO pre-qualified
Aurobindo Pharma gets USFDA nod for another ARV